Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China
Abstract The current analysis aimed to evaluate the cost-effectiveness of benmelstobart plus anlotinib and chemotherapy for patients with ES-SCLC from the Chinese health-care system perspective. A mathematical decision model that simulated patients’ 3-week transition in 20-year time horizon was cond...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2025-10-01
|
| Col·lecció: | Scientific Reports |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1038/s41598-025-20649-8 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|